Gyre Therapeutics clears regulatory path for first-in-class liver fibrosis drug in China
Gyre Therapeutics (NASDAQ:GYRE) is moving toward a landmark commercial entry in China after securing alignment with the Center for Drug Evaluation (CDE) on a conditional approval pathway for its lead anti-fibrotic candidate, Hydronidone (F351).











